Vitamin D status of ambulatory and nonambulatory mentally retarded children with and without carbamazepine treatment

• Published in: Annals of nutrition and metabolism Vol. 34; no. 4; pp. 216 - 220
• Main Authors: Lamberg-Allardt, C, Wilska, M, Saraste, K.L, Gronlund, T
• Format: Journal Article
• Language: English
• Published: Switzerland 1990
• Subjects: 24,25-dihydroxycholecalciferol; Adolescent; Adult; anticonvulsants; blood serum; Calcifediol - blood; calcitriol; Calcitriol - blood; Carbamazepine - therapeutic use; children with disabilities; Diet; Eating; Exercise; Humans; hydroxycholecalciferols; Intellectual Disability - drug therapy; Intellectual Disability - metabolism; mental retardation; nutrient intake; vitamin D; Vitamin D - blood; Vitamin D - physiology
• ISSN: 0250-6807; 1421-9697
• DOI: 10.1159/000177590

The subjects consisted of four groups: group 1 nonambulatory patients receiving carbamazepine; group 2 ambulatory patients receiving carbamazepine; group 3 nonambulatory patients receiving no drug, and group 4 ambulatory patients receiving no drugs. The serum 25-hydroxyvitamin D (25-OH-D) concentration was significantly lower in group 1 than in all other groups. There was no difference between the groups as regards the serum 1,25-dihydroxyvitamin D or 24,25-dihydroxyvitamin D concentration. Carbamazepine treatment lowers the serum 25-OH-D concentration, and inactivity which leads to a lower degree of time spent out-of-doors and thus a low exposure to sunlight still decreases the concentration. In this study a low dietary vitamin D intake probably was an aggravating factor.